Hungary Established in Hungary in 1913, Egis is a traditional Central Eastern European pharmaceutical company with an international footprint across the globe. As one of the four largest historical pharma companies in Hungary, the generic manufacturer now stands as a fully owned subsidiary of the French Servier Group. However, even today…
China 2009 marks 40 years of China’s liberalization and opening up under then-Premier Deng Xiaoping. Servier China also bears the distinction of having been established that year, celebrating its 40th anniversary in tandem with its host country. The success of Servier China is based on the quality of the people…
France With a feel-good factor sweeping French innovative pharma, the country’s iconic mid-cap biopharma standard-bearers are once more on the rise. These medium-sized national champions form part of G5 Santé, a club of companies altogether contributing some EUR 4.5 billion (USD 5 billion) worth of turnover to the home market and…
Thailand PharmaBoardroom last reported on Thailand in 2015, meeting country managers from across the healthcare and life sciences value chain. Here, we chart some of their career progressions since then. Sticking with Servier Guillaume Drianno Guillaume Drianno was Thailand country manager for French firm Servier between 2013 and 2017. Prior…
France The latest issue of Healthcare & Life Sciences Review France follows on from our March 2019 report and takes a closer look at the wider French life sciences value chain and the spirit of innovation and reform sweeping the nation. A reform-minded and business-oriented administration under President Emmanuel Macron…
France Not long ago, Laboratories Servier was considered a somewhat mysterious and opaque actor on the world pharmaceuticals stage. Privately owned, smaller and sleeker than many of its direct competitors, but nonetheless formidably successful, Servier has, for many years, been characterized by its discreet, understated approach and a rugged pragmatism and…
Europe Bringing together insights from the heads of some of Europe’s most prominent mid-cap pharma firms. The leaders of Ipsen, Genmab, Pierre Fabre, Esteve and Servier outline the strategic directions in which their companies are turning and how they are planning to ensure a successful future. David Meek, Ipsen David…
France Olivier Laureau, global president of Servier Group, outlines the impact of recent acquisitions, the significance of Servier’s recently-opened commercial subsidiary in the US, the ongoing importance of France to the global group, and Servier’s unique value proposition as a privately-owned R&D-focused company. The acquisition of Shire products also allowed…
Egypt Patrick Tete, managing director of Servier Egypt, highlights the cornerstones of his plan to transform the French company’s Egyptian affiliate, discussing its strengths and its place in Servier’s global operations. He also emphasises the need for more education and awareness amongst the population to reduce the prevalence of cardiovascular diseases…
Malaysia Kshitij Panse, director of Servier Malaysia discusses the company’s planned move into oncology, as well as their strategies to provide an all-round improved patient experience, through education, screening, and e-health. Oncology is the future, and we want to introduce the products in Servier’s pipeline to Malaysia as and when…
Algeria Guillaume Seillier, general director of Servier Algeria discusses recent changes in the affiliate, localization strategies, and Algeria’s importance to Servier’s regional and global operations. We would like to reach 100 percent local production by 2020 Could you introduce the current face of Servier and the main changes and emerging…
Turkey Gilles Renacco, the recently appointed general manager of Servier Turkey, provides insights into the successful localization process pioneered by Servier in the country, where 98 percent of the company’s products are nowadays locally manufactured. He also highlights the strategic importance of the country for the Servier Group, his key priorities…
See our Cookie Privacy Policy Here